DNA damage response永利皇冠app



DNA Damage Response Inhibition is an anti-cancer platform which could revolutionise the treatment of cancer. It works by exploiting DNA Damage Response defects which are specific to cancer cells, and kills them whilst sparing normal cells.1永利皇冠app



Every day, DNA in our cells is damaged thousands of times by natural causes and external factors. If not corrected, this DNA damage could eventually lead to cancer.1 The body has developed systems to protect the cells from DNA damage, called the DNA Damage Response or DDR.1永利皇冠app

A faulty DNA Damage Response system helps cancer develop, as it allows mutations that promote uncontrolled cell growth.2 Cancer cells with a DNA Damage Response deficiency are heavily reliant on remaining ‘back up’ DNA Damage Response systems.1永利皇冠app

DNA Damage Response Inhibition exploits these defects by blocking the remaining response systems cancer cells are relying on to survive, which in turn causes them to die. Healthy cells are not vulnerable to this type of treatment.1永利皇冠app


AstraZeneca is committed to investigating the potential of DNA Damage Response Inhibition across a range of tumour types. We currently have five compounds being investigated in clinical trials. The mechanism of action of DNA Damage Response Inhibitors suggests that they can be combined with other DNA Damage Response Inhibitors, immuno-oncology agents and targeted therapies.

Inhibiting stages in the DNA damage response pathway永利皇冠app


1.    O’Connor M, ‘Targeting The DNA Damage Response In Cancer’ (2015) 60 Molecular Cell

2.    Jackson S and Bartek J, ‘The DNA-Damage Response In Human Biology And Disease’ (2009) 461 Nature

3.    Vriend L and others, ‘WEE1 Inhibition And Genomic Instability In Cancer’ (2013) 1836 Biochimica et Biophysica Acta (BBA) - Reviews on Cancer

4.    De Witt Hamer P and others, ‘WEE1 Kinase Targeting Combined With DNA-Damaging Cancer Therapy Catalyzes Mitotic Catastrophe’ (2011) 17 Clinical Cancer Research

5.    A. Maréchal and L.Zou, ‘DNA Damage Sensing by the ATM and ATR Kinases’ (2013) Cold Spring Harb Perspect Biology.

6.    Weber A and Ryan A, ‘ATM And ATR As Therapeutic Targets In Cancer’ (2015) 149 Pharmacology & Therapeutics


and help us deliver life-changing medicines

Be among our employees who continue to make us an innovation-driven company that stands firmly among the world’s leaders in biopharmaceuticals.